Skip to main content

Research Repository

Advanced Search

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity

Fernando, I.N.; Lax, S.; Bowden, S.J.; Ahmed, I.; Steven, J.H.; Churn, M.; Brunt, A.M.; Agrawal, R.K.; Canney, P.; Stevens, A.; Rea, D.W.

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity Thumbnail


Authors

I.N. Fernando

S. Lax

S.J. Bowden

I. Ahmed

J.H. Steven

M. Churn

R.K. Agrawal

P. Canney

A. Stevens

D.W. Rea



Abstract

Aims
SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK centres, it recruited 2297 patients (1150 synchronous and 1146 sequential) between 2 July 1998 and 25 March 2004. SECRAB reported a positive therapeutic benefit of using adjuvant synchronous CRT in the management of breast cancer; 10-year local recurrence rates reduced from 7.1% to 4.6% (P = 0.012). The greatest benefit was seen in patients treated with anthracycline–cyclophosphamide, methotrexate, 5-fluorouracil (CMF) rather than CMF. The aim of its sub-studies reported here was to assess whether quality of life (QoL), cosmesis or chemotherapy dose intensity differed between the two CRT regimens.

Materials and methods
The QoL sub-study used EORTC QLQ-C30, EORTC QLQ-BR23 and the Women's Health Questionnaire. Cosmesis was assessed: (i) by the treating clinician, (ii) by a validated independent consensus scoring method and (iii) from the patients' perspective by analysing four cosmesis-related QoL questions within the QLQ-BR23. Chemotherapy doses were captured from pharmacy records. The sub-studies were not formally powered; rather, the aim was that at least 300 patients (150 in each arm) were recruited and differences in QoL, cosmesis and dose intensity of chemotherapy assessed. The analysis, therefore, is exploratory in nature.

Results
No differences were observed in the change from baseline in QoL between the two arms assessed up to 2 years post-surgery (Global Health Status: –0.05; 95% confidence interval –2.16, 2.06; P = 0.963). No differences in cosmesis were observed (via independent and patient assessment) up to 5 years post-surgery. The percentage of patients receiving the optimal course-delivered dose intensity (≥85%) was not significantly different between the arms (synchronous 88% versus sequential 90%; P = 0.503).

Conclusions
Synchronous CRT is tolerable, deliverable and significantly more effective than sequential, with no serious disadvantages identified when assessing 2-year QoL or 5-year cosmetic differences.

Journal Article Type Article
Acceptance Date Mar 20, 2023
Online Publication Date Mar 20, 2023
Publication Date 2023-06
Publicly Available Date May 30, 2023
Journal Clinical Oncology
Print ISSN 0936-6555
Electronic ISSN 1433-2981
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 35
Issue 6
Pages 397-407
DOI https://doi.org/10.1016/j.clon.2023.03.007
Keywords Breast cancer; chemotherapy; clinical trial; cosmesis; dose intensity; quality of life; radiotherapy; secondary outcomes; SECRAB
Publisher URL https://www.sciencedirect.com/science/article/pii/S0936655523001140

Files





You might also like



Downloadable Citations